Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy.

摘要: The breast cancer 1 and 2, early onset (BRCA1 BRCA2) genes are important for double-strand break repair by homologous recombination. Cells with inactivating mutations of the BRCA1 or BRCA2 tumor suppressor show increased sensitivity to Poly-ADP ribose polymerase (PARP)-inhibitors in vitro. Sporadic tumors promoter hypermethylation a similar phenotype familial patient termed "BRCAness." ovarian functional inactivation will also have BRCA-deficiency phenocopy. loss expression associated disrupt BRCA-associated DNA may sensitize BRCA-directed therapies. Thus, determination methylation status be an predictive classifier response PARP-inhibitor therapy. methylation, thereby functional, other implicated wider BRCA/homologous recombination (HR) pathway relevant prediction Here, we describe four optimal technologies assaying and/or genes.